DSGN - Latest News
Design Therapeutics, Inc. (DSGN), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $844.4M. Beta to the broader market is 1.59.
The article list below shows the most recent DSGN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent DSGN Headlines
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
globenewswire.com - Jun 30, 2026
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Cali
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
seekingalpha.com - Jun 24, 2026
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases.
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
globenewswire.com - May 28, 2026
CARLSBAD, Calif. , May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc.
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
benzinga.com - May 18, 2026
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
seekingalpha.com - May 18, 2026
Design Therapeutics, Inc.
How News Affects DSGN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track DSGN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked DSGN news questions
- What is the latest DSGN news headline?
- The most recent DSGN headline (Jun 30, 2026) is "Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the DSGN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What DSGN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual DSGN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.